GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.71 +0.04 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.71 +0.04 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
by Zacks Equity Research
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.
AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis
by Zacks Equity Research
AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.
Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal
by Zacks Equity Research
Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and GlaxoSmithKline (GSK) have performed compared to their sector so far this year.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion
by Zacks Equity Research
The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.
Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
by Zacks Equity Research
Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.36, moving +0.7% from the previous trading session.
Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug
by Zacks Equity Research
Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.
Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline
by Zacks Equity Research
Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.
Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.
GSK vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
Omicron Variant Puts COVID-19 Antibody Treatments in Focus
by Zacks Equity Research
We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Jazz (JAZZ) Enrols First Patient in Essential Tremor Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase IIb study to evaluate JZP385 for essential tremor.
Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.66 in the latest trading session, marking a +1.77% move from the prior day.